Cancer Science and Targeted Therapy Conference
6
PRISM Cancer Science and Targeted Therapy Conference September 06-07, 2021 | Virtual Time Zone: Melbourne VIC, Australia (GMT+10) Supporting Sponsor
Transcript of Cancer Science and Targeted Therapy Conference
PRISM
Cancer Science and Targeted Therapy Conference
September 06-07, 2021 | VirtualTime Zone: Melbourne VIC, Australia (GMT+10)
Supporting Sponsor
Cancer Science and Targeted Therapy Conference | September 06-07, 2021 | Virtual 02
September 06, 2021 | MondayDAY-01
09:00-09:15 Zoom Joining
09:15-09:30 Prof. Marco Falasca-Chair Introduction
09:30-09:35 Introduction to the Cancer Therapy 2021 by Prof. Marco Falasca, Curtin University, Perth, Australia
Chemoresistance
Chair: Marco Falasca, Curtin University, Perth, Australia
9:35-10:00 Systematic Modeling and Targeting Cell-cell Communication in Tumor Microenvironment Stephen T. C. Wong, Houston Methodist, Weill Cornell Medical College, TX
10:00-10:25 Paradigm Shift in the Study of P-glycoprotein Drug Transport: Implications of Induced Reversal from Drug Efflux to Uptake Suresh V. Ambudkar, NCI/NIH, MD, USA
10:25-10:50 Breaking the Cycle: Targeting of NDRG1 to Inhibit Bi-Directional Oncogenic Cross- Talk Between Pancreatic Cancer and Pancreatic Stellate Cells Des R. Richardson, Griffith University, Queensland, Australia
10:50-11:15 Targeting the Actin Cytoskeleton in Ovarian Cancer and Synergy with Microtubule Targeting Drugs Peter W. Gunning, UNSW Sydney, NSW, Australia
11:15-11:40 Treatment of Autologous Triple Negative Breast Cancer Animal Model with Combined Chemotherapy of Anacardic 6-Pentadecyl Salicylic Acid and Classical Chemotherapeutic Agents Libia Vega, Department of Toxicology, Centre for Research and Advanced Studies of the National Polytechnic Institute, Mexico
11:40-11:50 Coffee Break
Keynote Talk
11:50-12:20 Targeting Stromal-Tumour Interactions in Pancreatic Cancer – An Effective Therapeutic Approach? Minoti Apte, South Western Sydney Clinical School, Liverpool, Australia
12:20-12:45 Targeting Sphingolipid Metabolism in Acute Myeloid Leukemia Stuart Pitson, University of South Australia and SA Pathology, Adelaide, Australia
Cancer Science and Targeted Therapy Conference | September 06-07, 2021 | Virtual
Growth Factor Signalling and Lipid Signalling
Chair: Pieter Eichhorn, Curtin University, Perth, Australia
12:45-13:10 Regulation of Phosphoinositide 3-kinase Signaling in Breast Cancer Christina Mitchell, Monash University, Melbourne, Australia
13:10-13:35 Understanding the Role of PTEN Mutations in Cancer Development Antonella Papa, Monash University, Melbourne, Australia
13:35-13:55 CRISPR-based Gene Therapy for Breast Cancer via Light Triggered Liposomes B.Y. Yang, University of New South Wales, Australia
13:55-14:30 Lunch Break
14:30-14:55 Role of Oral Fluoropyrimidines in Adjuvant Therapy of Breast Cancer Masakazu Toi, Kyoto University Hospital, Japan
14:55-15:20 Cell and Tissue Reprogramming Using Extracellular Vesicles: Applications in Cancer and Regenerative Medicine David Greening, Baker Heart and Diabetes Institute, Melbourne, Australia
15:20-15:45 Pancreatic Cancer: Perspectives for a Brighter Prognosis Marco Falasca, Curtin University, Perth, Australia
15:45-15:55 Coffee Break
Tumor Microenvironment and Cancer Stem Cells
Chair: Tania Maffucci, Queen Mary University of London, UK
15:55-16:20 Novel Nanomedicine Shuts Down Metabolic Cellular Cross-talk Which Reduces Fibrosis and Pancreatic Tumour Progression Phoebe Phillips, Prince of Wales Clinical School, UNSW Medicine NSW, Australia
16:20-16:45 The Prognostic Value of S100A10 in Cancer Azrina Saraswati Karyadi, Indonesia International Institute for Life Sciences, Indonesia
16:45-17:10 Is it Possible to Predict Non Sentinel Node Positivity on the Basis of mRNA copy Numbers of CK19 Receptor in Breast Cancer? Isabelle Huynh, Princess Royal University Hospital, King’s College NHS Trust, UK
17:10-17:35 To Evaluated TruScreen Device (TS01) as Primary Screening for Cervical Cancer in Hospital during the COVID-19 Pandemic- Real-World Data Analysis Lixiu Peng, Chenzhou No.1 People’s Hospital, Hunan, China
17:35-18:00 Class II Phosphoinositide 3-kinase β and Cancer: A Novel Therapeutic Target? Tania Maffucci, Queen Mary University of London, UK
18:00-18:25 c-MET Activation Leads to the Establishment of a TGF-Beta Receptor Regulatory Network in Bladder Cancer Progression Pieter Eichhorn, Curtin University, Perth, Australia
18:25-18:30 Concluding Remarks
03
Cancer Science and Targeted Therapy Conference | September 06-07, 2021 | Virtual
08:45-08:55 Zoom Joining
08:55-09:00 Introduction
Novel Therapeutics Target in Cancer
Chair: Simon Keam, Peter MacCallum Cancer Centre, Melbourne, Australia
09:00-09:25 A Photoactivatable Microtubule-Targeting Rigidin Prodrug Alexander Kornienko, Texas State University, TX, USA
09:25-09:50 Targeting the MTORC2 Pathway in Obesity-Associated Colorectal Cancer Khosrow Rezvani, University of South Dakota, SD, USA
09:50-10:05 UBXN2A Inhibits Tumor Invasion and Metastasis by Targeting the mTORC2/AKT Signaling Pathway Sanam Sane, The University of South Dakota, USA
10:05-10:30 Mutant p53 in Prostate Cancer: Novel Therapeutics and a Clinically Relevant Model Javier Octavio Mejia-Hernandez, Peter MacCallum Cancer Centre, Melbourne, Australia
10:30-10:55 Copper Chelation Therapy as a Novel Therapeutic Strategy to Enhance Anti-Tumour Immune Response Orazio Vittorio, UNSW, Children’s Cancer Institute, Australia
10:55-11:10 Coffee Break
11:10-11:35 Small Molecule Drug Discovery, from Target Idea to Drug Candidate Brendon Monahan, Cancer Therapeutics | CTx CRC Ltd, Australia
11:35-11:50 Lithium Treatment of Cancer Mal Traill, Australia
Cancer Immunotherapy
Chair: Gabi Dachs, University of Otago, Christchurch, New Zealand
11:50-12:15 Immune Landscape Sculptured by the Peritoneal Microenvironment that Supports Metastases Arising from Colorectal Primary Tumours Robert G. Ramsay, Peter MacCallum Cancer Centre, Melbourne, Australia
12:15-12:40 High dose-rate Brachytherapy of Localized Prostate Cancer Converts Tumors from Cold to Hot Simon Keam, Peter MacCallum Cancer Centre, Melbourne, Australia
12:40-13:05 Cancer Immunotherapy by Targeting TGF-Β/Smad3 Hui Yao Lan, Li Ka Shing Institute of Health Sciences, The Chinese University of HongKong, Hong Kong
13:05-13:30 Lunch Break
September 07, 2021 | TuesdayDAY-02
04
Cancer Science and Targeted Therapy Conference | September 06-07, 2021 | Virtual
13:30-13:55 Regulation of the Hypoxia Transcription Factors by Ascorbate and Potential Implications for Cancer Patients Gabi Dachs, University of Otago, Christchurch, New Zealand
13:55-14:20 Development of Novel Small Molecule Cancer Immunopharmacotherapeutics Levon M. Khachigian, University of New South Wales, Sydney, Australia
14:20-14:45 Integrated Biobanking and Tumor Avatar Establishment of Colorectal Carcinoma Provides Excellent Tools for Modern Precision Medicine Michael Linnebacher, University Medicine Rostock, Germany
Cancer Targeted Therapy
14:45-15:10 Discovery of Novel Targetable Pathways and Drug Molecules for Childhood Leukaemias with Poor Outcome Klaartje Somers, Children’s Cancer Institute, Sydney, Australia
15:10-15:30 X-ray Triggered Lipid Nanoparticle Used for the Treatment of Colorectal Cancer Metastasis Rui Sang, UNSW Sydney, NSW, Australia
15:30-15:50 Clinical Efficacy of Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Carcinoma: A Systematic Review and Meta-Analysis of Clinical Trials Zhipeng Yan, The University of Hong Kong, China
15:50-16:05 Coffee Break
16:05-16:25 One-Carbon Metabolism and Tumor Immune Evasion Ting Wang, Tianjin Medical University, China
16:25-16:45 MCL1 Gene Co-Expression Module Stratifies Multiple Myeloma and Predicts Response to Proteasome Inhibitor-Based Therapy Xiaolong Fan, School of Life Sciences, Beijing Normal University, China
16:45-17:05 The Functional GRHL3-FLG Axis Predicts Targeted Therapy Response in Head and Neck Cancer Yuchen Bai, Peter MacCallum Cancer Center, Australia
Cancer Genetics
Chair: Levon M. Khachigian, University of New South Wales, Sydney, Australia
17:05-17:30 SMAD Proteins Directly Suppress PAX2 Transcription Downstream of Transforming Growth Factor Beta 1 Signalling in Renal Cell Carcinoma Michael Eccles, University of Otago, Christchurch, New Zealand
17:30-17:55 Pharmacologically Targetable Vulnerability in Prostate Cancer Carrying RB1-SUCLA2 Deletion Chiaki Takahashi, Cancer Research Institute, Kanazawa University, Japan
17:55-18:20 High Methylation of ZNF582/PAX1 in Cervical Cancer Affected Radio-chemo and Neoadjuvant Chemotherapy Sensitivity and Prognosis Na-Yi Yuan Wu, Xiangya Medical Laboratory, Central South University, China
18:20-18:25 Concluding Remarks
05
Conference SecretariatPrism Scientific Services Pty Ltd
Level 14, 380 St Kilda Road, Melbourne, VIC 3004, AustraliaTel: +61 383 913 150
Email: [email protected]: https://www.cancertherapyconference.com/
PRISM
